incretin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
2 December – Neville Callaghan, 77, racehorse trainer. 5 December – Rosemary Smith, 86, rally driver. 7 December – Thomas Kilroy, 89, playwright and novelist. 10 December Jonathan Irwin, 82, blood stock agent, auctioneer, stud owner, publisher and founder of the Jack and Jill Foundation. Syd Millar, 89, rugby union player (Ballymena, national team), coach (British & Irish Lions) and International Rugby Board chairman (2003–2007). Born in Northern Ireland. Bill McCarthy, 87, hurler (St Brendan's, Ardfert, Kerry junior team, Munster). 11 December – Frank Twomey, 68, children's television entertainer and comedian (Bosco, Bull Island). 16 December – Joseph Finnegan, 81, judge. 17 December – Maureen Flavin Sweeney, 100, postmistress and formerly a weather forecaster notable for advising on the D-Day landings. 20 December – Johnny Flaherty, 76, hurler (Kinnitty, Offaly senior team, Leinster). 21 December – Martin Feeley, 73, Olympic rower (1976) and surgeon. 27 December – Éamonn Draper, 83, actor and director. 28 December – Patrick Walsh, 92, Roman Catholic prelate, bishop of Down and Connor (1991–2008). 30 December – Paddy Murphy, 89, Gaelic footballer (Dromtarriffe, Duhallow, Cork senior team.
=== Asbestos === While Grace no longer makes asbestos or related products, at the time of its bankruptcy in 2001, it faced over 65,000 asbestos-related personal injury lawsuits involving over 129,000 claims. On April 2, 2001, Grace and its subsidiaries in the United States filed voluntary petitions for Chapter 11 Bankruptcy reorganization in the Bankruptcy Court for the District of Delaware. The company was trying to find a resolution through federal court-supervised reorganization in response to the quickly growing number of asbestos-related bodily injury claims. On September 19, 2008, Grace filed a revised plan of reorganization to the same court, jointly with the asbestos injury claimants. In January 2011, the court issued an order in favor of the new plan and in January 2012, the court denied all appeals and affirmed the plan. After a motion for reconsideration, the plan was reaffirmed on June 11, 2012. On February 3, 2014, Grace emerged from the asbestos-related Chapter 11 bankruptcy, which took more than 12 years. Under the plan of reorganization approved by the court, all parties filings the asbestos-related claims were to direct their inquiry to either an asbestos personal injury trust or a separate asbestos property damage trust.
Fury realizes that it was too easy to get in, just before his team is captured and stripped of their weapons. Viper reveals to him that she will release the virus even if they are paid, and locks Fury and his team in a freezer. Fury reveals that in place of his missing left eye, he keeps an explosive with which they can escape. Reaching Viper's control room, Fury and Viper fight until she gets hold of a gun and shoots him. However, it turns out to be Fury's Life Model Decoy. Fury incapacitates Zola and captures Viper, and Neville uses her telepathy to draw the code to abort the detonation from Viper's mind. The Helicarrier arrives and captures the rest of Hydra's forces, but Viper escapes with the body of her father. Fury decides to return to S.H.I.E.L.D. to counter the new threat of Hydra, while Viper is shown to have restored her father, Baron Wolfgang Von Strucker, to life.
Fe2O3 + 2 Al → 2 Fe + Al2O3 Alternatively pig iron may be made into steel (with up to about 2% carbon) or wrought iron (commercially pure iron). Various processes have been used for this, including finery forges, puddling furnaces, Bessemer converters, open hearth furnaces, basic oxygen furnaces, and electric arc furnaces. In all cases, the objective is to oxidize some or all of the carbon, together with other impurities. On the other hand, other metals may be added to make alloy steels.
=== Overall survival === Overall survival is based on death from any cause, not just the condition being treated, thus it picks up death from side effects of the treatment, and effects on survival after relapse.
Sources: en.wikipedia.org
== Tissue distribution == The POMC gene is expressed in both the anterior and intermediate lobes of the pituitary gland. Its protein product is primarily synthesized by corticotropic cells in the anterior pituitary, but it is also produced in several other tissues:
== History == The word comes from the Greek ἀφροδισιακόν, aphrodisiakon 'sexual, aphrodisiac', from aphrodisios 'pertaining to Aphrodite', the Greek goddess of love. Throughout human history, food, drinks, and behaviors have had a reputation for making sex more attainable and/or pleasurable. However, from a historical and scientific standpoint, the alleged results may have been mainly due to mere belief on the part of their users that they would be effective (a placebo effect). Likewise, many medicines are reported to affect libido in inconsistent or idiopathic ways: enhancing or diminishing overall sexual desire, depending on the circumstances. For example, bupropion (Wellbutrin) is known as an antidepressant that can counteract other co-prescribed antidepressants with libido-diminishing effects. However, because bupropion increases libido only when it is already impaired by related medications, it is not generally classed as an aphrodisiac. Ancient civilizations like Chinese, Indian, Egyptian, Roman, and Greek cultures believed that certain substances could provide the key to improving sexual desire, sexual pleasure, and/or sexual behavior. This was important because some men suffered from erectile dysfunction and could not reproduce. Men who could not impregnate their wives and father large families were seen as failures, whereas those who could were respected. Hence, a stimulant was needed. Others who did not suffer from this also desired performance enhancers.
Biological research in cold seeps and hydrothermal vents has been mostly focused on the microbiology and the prominent macro-invertebrates thriving on chemosynthetic microorganisms. Much less research has been done on the smaller benthic fraction at the size of the meiofauna (<1 mm). A community composition's orderly shift from one set of species to another is called ecological succession. The first type of organism to take advantage of this deep-sea energy source is bacteria. Aggregating into bacterial mats at cold seeps, these bacteria metabolize methane and hydrogen sulfide (another gas that emerges from seeps) for energy. This process of obtaining energy from chemicals is known as chemosynthesis.
Sales were legalized in Colorado in March 2015. On 25 March 2015, alcohol wholesalers and distributors in the state of Maryland announced an agreement to voluntarily ban the distribution and sale of powdered alcohol. Concerns included the potential for misuse by minors, the ease of using the powder to bring alcohol into public events or to spike drinks, and the potential to snort the powder. At the same time, a bill to ban Palcohol for one year was under consideration in the Maryland House of Delegates. In September 2015, the New Hampshire Liquor Commission banned the sale of Palcohol. By November 2015, most states had introduced legislation and laws to regulate or ban powdered alcohol. Twenty-seven have banned powdered alcohol, 2 more have placed temporary 1-year bans on the product and 3 have included powdered alcohol under their statutory definitions of alcohol meaning that it is covered by existing alcohol regulations.
== Background == During the early 19th century, a diverse group of Sotho-, Nguni- and Tswana-speaking tribes settled in the Caledon River region. The latter two, which formed the minority of the population, were gradually assimilated by the culturally dominant Sotho. King Moshoeshoe I united the various Sotho-speaking chieftainships into a single nation during a period of political turbulence known as Lifaqane. He transformed the denigratory exonym of Sotho into the name of the nascent Basuto nation. In 1833, missionaries from the Paris Evangelical Missionary Society began setting their outposts in Basuto lands following Moshoeshoe's invitation. They promoted a combination of Christianity, Western civilization, and commerce. They saw Basuto customs linked to obligatory labor and the dependence of the population on their chiefs as evil. They sought to undermine them by promoting private property, the commodization of production and closer economic ties with European settlers. In the 1820s, the Basuto faced cattle raids from the Koranna and first encountered horses and guns in a combat setting. They obtained horses and guns of their own, and began stockpiling gunpowder. By 1843, Moshoeshoe had accumulated more horses and guns than any other chieftain in South Africa, but the guns were outdated flintlocks, which had flooded the South African market after the introduction of percussion lock muskets.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.